Special clinical nutrition formula for bone cancer and preparation method thereof

Abstract

The invention discloses a special clinical nutrition formula for bone cancer and a preparation method thereof. The formula comprises the following components in parts by weight: 40-60 parts of a solvent and 1-5 parts of an additive, carbohydrate 2-28 parts, 10-45 parts of protein, 0.1 to 3 parts of arginine; 1 to 5 parts of glutamine; 0.2 to 0.5 part of beta-hydroxy-beta-methyl calcium butyrate, 0.1 to 2 parts of unsaturated fatty acid, 0.008 to 0.3 part of compound vitamin, 2.5 to 4 parts of selenium, 0.02 to 1 part of L-carnitine, 8 to 12 parts of yellow or green vegetables, 6 to 10 parts ofdietary fiber, 0.03 to 3.5 parts of new resource food and 1 to 15 parts of medicinal and edible components. According to the special clinical nutrition formula, with the reasonable diet blending, thenutrition status of the bone cancer patient is improved, the adverse reaction during the chemotherapy is reduced, the prognosis of the patient is improved, the subsequent reasonable nutrition supportis provided while the abnormal metabolism of the tumor is regulated, the growth of the tumor is inhibited, and the survival time of the patient is finally prolonged.

Description

technical field [0001] The invention relates to the field of formula food for special medical purposes, in particular to a bone cancer-specific clinical nutritional formula and a preparation method thereof. Background technique [0002] Bone cancer, also known as bone tumor, refers to the skeletal system, like other organs, suffering from tumors of any tissue components or metastatic lesions from other organs. Tumors involving bone can occur in bone cells, hematopoietic components of bone, cartilage, and fibrous or synovial components. It can be primary or metastatic; it can be benign or malignant. [0003] Benign bone tumors include osteochondroma, enchondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, nonossifying fibroma (fibrous cortical defect), and benign giant cell tumor of bone. Primary malignant bone tumors include multiple myeloma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, lymphoma of bone, malignant...

AI Technical Summary

Problems solved by technology

[0007] Although the incidence rate of osteosarcoma is not high, it is quite dangerous. The survival rate of advanced patients is very low. For patients with bone pain who are not treated after diagnosis, the cancer cells will metastasize to the lung within six months to one year, resulting in death of the patient, and even amputation After surgery, the vast majority of advanced patients will still die of cancer cell lung metastasis or multi-site bone metastasis